Katerina Politi, PhD

• Abhijit Patel
• Anna Arnal Estape
• Anna Wurtz
• Anne Chiang
• Barbara Burtness
• Curtis Jamison Perry
• Daniel Boffa
• Daniel Zelterman
• David Rimm
• Don Nguyen
• Edward Kaftan
• Fangyong Li
• Francesc Lopez-Giraldez
• Francisco Exposito
• Guoping Cai
• Harriet Kluger
• Jeffrey Townsend
• Kurt Schalper
• Lynn D. Wilson
• Mark A Lemmon
• Michael Chiorazzi
• Michael Grant
• Paul Stockhammer
• Robert Homer
• Rolando Garcia Milian
• Roy S. Herbst
• Sampada Chande
• Sarah Goldberg
• Scott Gettinger
• Shrikant Mane
• Veronica Chiang
• Yuko Tsutsui
• Yuval Kluger
• Zenta Walther

Cell Transformation, Neoplastic; Lung Neoplasms; Pathology; Molecular Targeted Therapy

• Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironmentChiorazzi M, Martinek J, Krasnick B, Zheng Y, Robbins K, Robbins K, Qu R, Qu R, Kaufmann G, Skidmore Z, Juric M, Henze L, Henze L, Brösecke F, Adonyi A, Zhao J, Shan L, Sefik E, Mudd J, Bi Y, Bi Y, Goedegebuure S, Griffith M, Griffith O, Oyedeji A, Fertuzinhos S, Fertuzinhos S, Garcia-Milian R, Boffa D, Detterbeck F, Dhanasopon A, Dhanasopon A, Blasberg J, Judson B, Gettinger S, Politi K, Politi K, Kluger Y, Kluger Y, Palucka K, Palucka K, Fields R, Fields R, Flavell R, Flavell R. Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment. Journal For ImmunoTherapy Of Cancer 2023, 11: e006921. PMID: 37487666, PMCID: PMC10373695, DOI: 10.1136/jitc-2023-006921.
• Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.Stockhammer P, Grant M, Wurtz A, Foggetti G, Expósito F, Gu J, Chung S, Li F, Walther Z, Gettinger S, Politi K, Goldberg S. Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer. Journal Of Clinical Oncology 2023, 41: 9104-9104. DOI: 10.1200/jco.2023.41.16_suppl.9104.
• A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C -mutant non–small-cell lung cancer.Goldberg S, Punekar S, Velcheti V, Riess J, Scilla K, Carlisle J, Politi K, Lee J, Myers T, Paradiso L, Burtness B. A phase 1a/1b study of aurora kinase A inhibitor VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C -mutant non–small-cell lung cancer. Journal Of Clinical Oncology 2023, 41: tps9140-tps9140. DOI: 10.1200/jco.2023.41.16_suppl.tps9140.
• LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy.Besse B, Castro G, Felip E, Politi K, Takahashi T, Wang J, Dean E, Deans M, Broadhurst H, Thiyagarajah P, Forde P. LATIFY: Phase 3 study of ceralasertib + durvalumab vs docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer that progressed on or after anti-PD-(L)1 and platinum-based therapy. Journal Of Clinical Oncology 2023, 41: tps9161-tps9161. DOI: 10.1200/jco.2023.41.16_suppl.tps9161.
• Abstract 1172: Oncogenic context shapes the fitness landscape of tumor suppressionBlair L, Juan J, Sebastian L, Tran V, Nie W, Wall G, Gerceker M, Lai I, Apilado E, Grenot G, Amar D, Foggetti G, Do Carmo M, Ugur Z, Deng D, Chenchik A, Zafra M, Dow L, Politi K, MacQuitty J, Petrov D, Winslow M, Rosen M, Winters I. Abstract 1172: Oncogenic context shapes the fitness landscape of tumor suppression. Cancer Research 2023, 83: 1172-1172. DOI: 10.1158/1538-7445.am2023-1172.
• Abstract 126: Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapyFisk J, Gaffney S, Politi K, Gettinger S, de Miguel F, Townsend J. Abstract 126: Extreme selection constrains ability of EGFR-driven lung adenocarcinoma to diversify in response to erlotinib therapy. Cancer Research 2023, 83: 126-126. DOI: 10.1158/1538-7445.am2023-126.
• Abstract 451: AICAR targets oncogenic signaling pathways of MUC1-CTAftab F, Rodriguez-Fuguet A, Silva L, Kobayashi I, Sun J, Politi K, Levantini E, Zhang W, Kobayashi S, Zhang W. Abstract 451: AICAR targets oncogenic signaling pathways of MUC1-CT. Cancer Research 2023, 83: 451-451. DOI: 10.1158/1538-7445.am2023-451.
• Abstract 1124: PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cellsExposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano J, Ortega J, Andradas V, Amat R, Redin E, Leon S, Legarra N, García J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Felip E, Lasarte J, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. Abstract 1124: PTEN loss confers resistance to anti-PD-1 therapy in NSCLC by increasing tumor infiltration of T regulatory cells. Cancer Research 2023, 83: 1124-1124. DOI: 10.1158/1538-7445.am2023-1124.
• Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion MutationsGrant M, Aredo J, Starrett J, Stockhammer P, K. Rosenburgh I, Wurtz A, Piper-Valillo A, Piotrowska Z, Falcon C, Yu H, Aggarwal C, Scholes D, Patil T, Nguyen C, Phadke M, Li F, Neal J, Lemmon M, Walther Z, Politi K, Goldberg S. Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations. Clinical Cancer Research 2023, 29: of1-of8. PMID: 36913537, PMCID: PMC10493186, DOI: 10.1158/1078-0432.ccr-22-3497.
• An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1Aftab F, Rodriguez-Fuguet A, Silva L, Kobayashi I, Sun J, Politi K, Levantini E, Zhang W, Kobayashi S, Zhang W. An intrinsic purine metabolite AICAR blocks lung tumour growth by targeting oncoprotein mucin 1. British Journal Of Cancer 2023, 128: 1647-1664. PMID: 36810913, PMCID: PMC10133251, DOI: 10.1038/s41416-023-02196-z.
• Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancerAdua S, Arnal-Estapé A, Zhao M, Qi B, Liu Z, Kravitz C, Hulme H, Strittmatter N, López-Giráldez F, Chande S, Albert A, Melnick M, Hu B, Politi K, Chiang V, Colclough N, Goodwin R, Cross D, Smith P, Nguyen D. Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer. Nature Communications 2022, 13: 7690. PMID: 36509758, PMCID: PMC9744876, DOI: 10.1038/s41467-022-34889-z.
• Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutationsvan Alderwerelt van Rosenburgh I, Lu D, Grant M, Stayrook S, Phadke M, Walther Z, Goldberg S, Politi K, Lemmon M, Ashtekar K, Tsutsui Y. Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. Nature Communications 2022, 13: 6791. PMID: 36357385, PMCID: PMC9649653, DOI: 10.1038/s41467-022-34398-z.
• EP08.02-125 Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung CancerStockhammer P, Grant M, Wurtz A, Foggetti G, Chung S, Li F, Gettinger S, Politi K, Goldberg S. EP08.02-125 Tumor Suppressor Gene Alterations Identified at Disease Progression Impact Outcomes in Patients with EGFR-mutant Lung Cancer. Journal Of Thoracic Oncology 2022, 17: s462-s463. DOI: 10.1016/j.jtho.2022.07.808.
• Abstract 1094: SMARCA4 -mediated chromatin remodeling regulates osimertinib resistance in EGFR -mutant lung adenocarcinomade Miguel F, Cai W, Melnick M, Robles-Oteiza C, Wurtz A, Toki M, Rimm D, Homer R, Nguyen D, Politi K. Abstract 1094: SMARCA4 -mediated chromatin remodeling regulates osimertinib resistance in EGFR -mutant lung adenocarcinoma. Cancer Research 2022, 82: 1094-1094. DOI: 10.1158/1538-7445.am2022-1094.
• Abstract 1540: Accumulation of the long noncoding RNA Malat1 is a central driver and therapeutic target in metastatic lung cancerMartínez-Terroba E, de Miguel F, Robles-Oteiza C, Politi K, Dimitrova N. Abstract 1540: Accumulation of the long noncoding RNA Malat1 is a central driver and therapeutic target in metastatic lung cancer. Cancer Research 2022, 82: 1540-1540. DOI: 10.1158/1538-7445.am2022-1540.
• Abstract 5848: Inhibition of the CRM1 nuclear export protein can treat mutant KRAS tumors through stabilizing the DLC1 tumor suppressor proteinTripathi B, Hirsh N, Qian X, Wang D, Durkin M, de Miguel F, Politi K, Doroshow J, Lowy D. Abstract 5848: Inhibition of the CRM1 nuclear export protein can treat mutant KRAS tumors through stabilizing the DLC1 tumor suppressor protein. Cancer Research 2022, 82: 5848-5848. DOI: 10.1158/1538-7445.am2022-5848.
• Abstract 839: YES1 is a novel druggable oncogene in small cell lung cancerRedin E, Garrido-Martin E, Valencia K, Redrado M, Solorzano J, Carias R, Exposito F, Serrano D, Otegui N, Ares L, Politi K, Montuenga L, Calvo A. Abstract 839: YES1 is a novel druggable oncogene in small cell lung cancer. Cancer Research 2022, 82: 839-839. DOI: 10.1158/1538-7445.am2022-839.
• Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.Grant M, Aredo J, Starrett J, Wurtz A, Piotrowska Z, Piper-Vallillo A, Yu H, Falcon C, Patil T, Nguyen C, Aggarwal C, Scholes D, Li F, Phadke M, Neal J, Walther Z, Politi K, Goldberg S. Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P. Journal Of Clinical Oncology 2022, 40: e21112-e21112. DOI: 10.1200/jco.2022.40.16_suppl.e21112.
• 936 Stromal remodeling regulates dendritic cell abundance in the tumor microenvironmentPapadas A, Deb G, Officer A, Hope C, Emmerich P, Cicala A, Wiesner J, Arauz G, Pagenkopf A, Matkowskyj K, Deming D, Politi K, Abrams S, Harismendy O, Asimakopoulos F. 936 Stromal remodeling regulates dendritic cell abundance in the tumor microenvironment. Journal For ImmunoTherapy Of Cancer 2021, 9: a982-a982. DOI: 10.1136/jitc-2021-sitc2021.936.
• Immune Therapy: What Can We Learn From Acquired Resistance?Grant M, Politi K, Gettinger S. Immune Therapy: What Can We Learn From Acquired Resistance? 2021, 75-114. DOI: 10.1007/978-3-030-74028-3_5.
• Abstract 1613: A hypoxia-driven transcriptional program characterizes acquired resistance to immune checkpoint inhibitors in lung cancerRobles-Oteiza C, Hastings K, Kaech S, Politi K. Abstract 1613: A hypoxia-driven transcriptional program characterizes acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Research 2021, 81: 1613-1613. DOI: 10.1158/1538-7445.am2021-1613.
• Abstract 1572: Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapyBrady M, Momcilovic M, Montemurro C, Yokoyama Y, Christofk H, Politi K, Dugan M, Lisberg A, Wild R, Shackelford D. Abstract 1572: Broad glutamine pathway inhibition by DRP-104 results in anti-tumor activity in hypermetabolic lung tumors resistant to PD-1 or osimertinib therapy. Cancer Research 2021, 81: 1572-1572. DOI: 10.1158/1538-7445.am2021-1572.
• Abstract 2508: Targeting mutant KRAS tumors by inhibiting cytoplasmic EZH2, which directly methylates and destabilizes the DLC1 tumor suppressor proteinTripathi B, Bhargava D, Qian X, Wang D, Durkin M, de Miguel F, Politi K, Walters K, Doroshow J, Lowy D. Abstract 2508: Targeting mutant KRAS tumors by inhibiting cytoplasmic EZH2, which directly methylates and destabilizes the DLC1 tumor suppressor protein. Cancer Research 2021, 81: 2508-2508. DOI: 10.1158/1538-7445.am2021-2508.
• Abstract 1094: Genetic determinants of EGFR -driven lung cancer growth and therapeutic response in v ivoFoggetti G, Li C, Cai H, Lin W, Ayeni D, Hastings K, Andrejka L, Maghini D, Homer R, Petrov D, Winslow M, Politi K. Abstract 1094: Genetic determinants of EGFR -driven lung cancer growth and therapeutic response in v ivo. Cancer Research 2020, 80: 1094-1094. DOI: 10.1158/1538-7445.am2020-1094.
• Abstract A13: ASCL1 confers tolerance to tyrosine kinase inhibitors in EGFR mutant lung cancerHu B, de Miguel F, Liu Z, Chan L, Melnick M, Yan Q, Nguyen D, Fan R, Politi K. Abstract A13: ASCL1 confers tolerance to tyrosine kinase inhibitors in EGFR mutant lung cancer. Cancer Research 2020, 80: a13-a13. DOI: 10.1158/1538-7445.camodels2020-a13.
• Abstract IA10: Modeling sensitivity and resistance to systemic therapies in lung cancerPoliti K. Abstract IA10: Modeling sensitivity and resistance to systemic therapies in lung cancer. Cancer Research 2020, 80: ia10-ia10. DOI: 10.1158/1538-7445.camodels2020-ia10.
• Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.Mack P, Redman M, Moon J, Goldberg S, Herbst R, Melnick M, Walther Z, Hirsch F, Politi K, Kelly K, Gandara D. Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. Journal Of Clinical Oncology 2020, 38: 9532-9532. DOI: 10.1200/jco.2020.38.15_suppl.9532.
• Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR MutationsStarrett J, Guernet A, Cuomo M, Poels K, K. Rosenburgh I, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar K, Gaefele M, Ayeni D, Stewart T, Kuhlmann A, Kaech S, Unni A, Homer R, Lockwood W, Michor F, Goldberg S, Lemmon M, Smith P, Cross D, Politi K. Drug Sensitivity and Allele‐specificity of First‐line Osimertinib Resistance EGFR Mutations. The FASEB Journal 2020, 34: 1-1. DOI: 10.1096/fasebj.2020.34.s1.00612.
• IA31 Genetic Contributors to Tumor Progression and Drug Resistance in EGFR Mutant Lung CancerPoliti K. IA31 Genetic Contributors to Tumor Progression and Drug Resistance in EGFR Mutant Lung Cancer. Journal Of Thoracic Oncology 2020, 15: s10. DOI: 10.1016/j.jtho.2019.12.029.
• B32 Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR MutationsStarrett J, Guernet A, Cuomo M, Poels K, Rosenburgh I, Nagelberg A, Farnsworth D, Price K, Khan H, Ashtekar K, Gaefele M, Ayeni D, Stewart T, Kuhlmann A, Kaech S, Unni A, Homer R, Lockwood W, Michor F, Goldberg S, Lemmon M, Smith P, Cross D, Politi K. B32 Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations. Journal Of Thoracic Oncology 2020, 15: s36. DOI: 10.1016/j.jtho.2019.12.097.
• B30 The Role of SMARCA4 as an EGFR-Independent Mechanism of Resistance to Osimertinibde Miguel F, Hu B, Cai W, Sun N, Melnick M, Nguyen D, Xiao A, Politi K. B30 The Role of SMARCA4 as an EGFR-Independent Mechanism of Resistance to Osimertinib. Journal Of Thoracic Oncology 2020, 15: s35-s36. DOI: 10.1016/j.jtho.2019.12.095.
• ES11.04 Mechanisms for Resistance to TKI and ICIPoliti K. ES11.04 Mechanisms for Resistance to TKI and ICI. Journal Of Thoracic Oncology 2019, 14: s41. DOI: 10.1016/j.jtho.2019.08.118.
• Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasisWingrove E, Liu Z, Nguyen D, Arnal-Estape A, Patel K, Melnick M, Politi K, Valiente M, Kluger H, Chiang V. Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis. 2019, 4552-4552. DOI: 10.1158/1538-7445.sabcs18-4552.
• Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasisWingrove E, Liu Z, Nguyen D, Arnal-Estape A, Patel K, Melnick M, Politi K, Valiente M, Kluger H, Chiang V. Abstract 4552: BMX-Seq as a new resource for deciphering the transcriptomic hallmarks of tumor plasticity and stromal interactions in brain metastasis. Cancer Research 2019, 79: 4552-4552. DOI: 10.1158/1538-7445.am2019-4552.
• Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain MetastasisWingrove E, Liu Z, Patel K, Arnal‐Estape A, Melnick M, Politi K, Monteiro C, Zhu L, Valiente M, Kluger H, Chiang V, Nguyen D. Transcriptomic Hallmarks of Tumor Plasticity and Stromal Interactions in Brain Metastasis. The FASEB Journal 2019, 33: 368.8-368.8. DOI: 10.1096/fasebj.2019.33.1_supplement.368.8.
• OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403Goldberg S, Redman M, Lilenbaum R, Politi K, Stinchcombe T, Horn L, Chen E, Mashru S, Gettinger S, Melnick M, Miao J, Moon J, Kelly K, Gandara D. OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403. Journal Of Thoracic Oncology 2018, 13: s343-s344. DOI: 10.1016/j.jtho.2018.08.290.
• Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancerHastings K, Gettinger S, Jungmin C, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick M, Schlessinger J, Goldberg S, Chiang A, Melero I, Agorreta J, Montuenga L, Lifton R, Ferrone S, Kavathas P, Rimm D, Kaech S, Schalper K, Herbst R, Politi K. Abstract A09: Impaired HLA Class I antigen processing and presentation as a mechanism of acquired Rrsistance to immune checkpoint inhibitors in lung cancer. Cancer Immunology Research 2018, 6: a09-a09. DOI: 10.1158/2326-6074.tumimm17-a09.
• Differential outcomes in patients with uncommon EGFR exon 19 mutations.Stewart T, Truini A, DeVeaux M, Zelterman D, Walther Z, Wurtz A, Gettinger S, Politi K, Goldberg S. Differential outcomes in patients with uncommon EGFR exon 19 mutations. Journal Of Clinical Oncology 2018, 36: 9056-9056. DOI: 10.1200/jco.2018.36.15_suppl.9056.
• The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)Aisner DL, investigators F, Sholl L, Berry L, Rossi M, Chen H, Fujimoto J, Moreira A, Ramalingam S, Villaruz L, Otterson G, Haura E, Politi K, Glisson B, Cetnar J, Garon E, Schiller J, Waqar S, Sequist L, Brahmer J, Shyr Y, Kugler K, Wistuba I, Johnson B, Minna J, Kris M, Bunn P, Kwiatkowski D. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2). Clinical Cancer Research 2018, 24: 1038-1047. PMID: 29217530, PMCID: PMC7008001, DOI: 10.1158/1078-0432.ccr-17-2289.
• P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic FactorKris M, Aisner D, Sholl L, Berry L, Rossi M, Chen H, Fujimoto J, Moreira A, Ramalingam S, Villaruz L, Otterson G, Haura E, Politi K, Glisson B, Cetnar J, Garon E, Schiller J, Waqar S, Sequist L, Brahmer J, Shyr Y, Kugler K, Wistuba I, Johnson B, Minna J, Bunn P, Kwiatkowski D. P3.03-007 LCMC2: Expanded Profiling of Lung Adenocarcinomas Identifies ROS1 and RET Rearrangements and TP53 Mutations as a Negative Prognostic Factor. Journal Of Thoracic Oncology 2017, 12: s2275. DOI: 10.1016/j.jtho.2017.09.1633.
• P3.01-046 Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without CetuximabMack P, Miao J, Banks K, Burich R, Politi K, Raymond V, Dix D, Lanman R, Moon J, Melnick M, Truini A, Redman M, Goldberg S, Gandara D, Kelly K. P3.01-046 Longitudinal Analysis of Plasma CtDNA in EGFR-Mutant NSCLC: SWOG S1403 Trial of Afatinib with or Without Cetuximab. Journal Of Thoracic Oncology 2017, 12: s2219. DOI: 10.1016/j.jtho.2017.09.1487.
• OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLCElamin Y, Robichaux J, Lam V, Tsao A, Lu C, Blumenschein G, Kurie J, Brahmer J, Li S, Chen T, Estrada-Bernal A, Truini A, Nilsson M, Le A, Tan Z, Zhang S, Doebele R, Politi K, Yang Z, Liu S, Wong K, Heymach J. OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC. Journal Of Thoracic Oncology 2017, 12: s1776. DOI: 10.1016/j.jtho.2017.09.394.
• Genome-Wide RNA Interference: Functional Genomics in the Postgenomics Era.Politi K, Wajapeyee N. Genome-Wide RNA Interference: Functional Genomics in the Postgenomics Era. Cold Spring Harbor Protocols 2017, 2017: pdb.top097550. PMID: 28864574, DOI: 10.1101/pdb.top097550.
• 1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNAGoldberg S, Narayan A, Kole A, Decker R, Teysir J, Carriero N, Lee A, Nemati R, Nath S, Mane S, Deng Y, Sukumar N, Zelterman D, Boffa D, Politi K, Gettinger S, Wilson L, Herbst R, Patel A. 1341P Assessing response to immunotherapy in patients with non-small cell lung cancer using circulating tumor DNA. Annals Of Oncology 2017, 28: v478. DOI: 10.1093/annonc/mdx380.043.
• YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing.Fan P, Narzisi G, Jayaprakash A, Venturini E, Robine N, Smibert P, Germer S, Jordan E, Wang L, Jungbluth A, Spraggon L, Lovly C, Kris M, Yu H, Riely G, Varmus H, Politi K, Ladanyi M. YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing. Journal Of Clinical Oncology 2017, 35: 9043-9043. DOI: 10.1200/jco.2017.35.15_suppl.9043.
• Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers.Datar I, Mani N, Henick B, Wurtz A, Kaftan E, Herbst R, Rimm D, Gettinger S, Politi K, Schalper K. Measurement of PD-1, TIM-3 and LAG-3 protein in non-small cell lung carcinomas (NSCLCs) with acquired resistance to PD-1 axis blockers. Journal Of Clinical Oncology 2017, 35: e14611-e14611. DOI: 10.1200/jco.2017.35.15_suppl.e14611.
• Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC).Henick B, Goldberg S, Narayan A, Rossi C, Rodney S, Kole A, Politi K, Gettinger S, Herbst R, Patel A. Circulating tumor DNA (ctDNA) to monitor treatment response and progression in patients treated with tyrosine kinase inhibitors (TKIs) and immunotherapy for EGFR-mutant non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2017, 35: e20652-e20652. DOI: 10.1200/jco.2017.35.15_suppl.e20652.
• MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)Gettinger S, Choi J, Mani N, Datar I, Kaftan E, Goldberg S, Zelterman D, Politi K, Lifton R, Rimm D, Herbst R, Schalper K. MA15.06 Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC). Journal Of Thoracic Oncology 2017, 12: s430-s431. DOI: 10.1016/j.jtho.2016.11.501.
• MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung AdenocarcinomasHastings K, Choi J, Wurtz A, Walther Z, Cai G, Oliva I, Zhao Z, Gaffney S, Iamarino A, Zhao S, Bi M, Goldberg S, Chiang A, Liu Z, Townsend J, Schlessinger J, Lifton R, Herbst R, Gettinger S, Politi K. MA16.02 Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas. Journal Of Thoracic Oncology 2017, 12: s435. DOI: 10.1016/j.jtho.2016.11.507.
• P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT BiomarkersChoi J, Sowell R, Truini A, Schalper K, Wurtz A, Cai G, Perry C, Datar I, Hastings K, Melnick M, Kaftan E, Kavathas P, Kaech S, Rimm D, Goldberg S, Chiang A, Lifton R, Chen L, Herbst R, Politi K, Gettinger S. P3.02c-088 Acquired Resistance to Programmed Death-1 Axis Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Topic: IT Biomarkers. Journal Of Thoracic Oncology 2017, 12: s1331-s1332. DOI: 10.1016/j.jtho.2016.11.1884.
• P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403 Topic: EGFR ClinicalGoldberg S, Moon J, Lilenbaum R, Politi K, Melnick M, Stinchcombe T, Horn L, Chen E, Miao J, Redman M, Kelly K, Gandara D. P3.02b-052 Afatinib with or without Cetuximab for First-Line Treatment of EGFR-Mutant NSCLC: Interim Safety Results of SWOG S1403 Topic: EGFR Clinical. Journal Of Thoracic Oncology 2017, 12: s1220-s1221. DOI: 10.1016/j.jtho.2016.11.1719.
• MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung CancerSuda K, Rozeboom L, Rivard C, Yu H, Melnick M, Hinz T, Ellison K, Chan D, Politi K, Heasley L, Mitsudomi T, Hirsch F. MA15.11 Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s433-s434. DOI: 10.1016/j.jtho.2016.11.505.
• Tumor Genotyping Analysis Using Cytological Specimens of Primary and Metastatic Lung AdenocarcinomasRaad R, Walther Z, Gettinger S, Politi K, Puchalski J, Homer R, Cai G. Tumor Genotyping Analysis Using Cytological Specimens of Primary and Metastatic Lung Adenocarcinomas. Journal Of The American Society Of Cytopathology 2016, 5: s53. DOI: 10.1016/j.jasc.2016.07.122.
• HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies.Xia B, Wurtz A, Gettinger S, Herbst R, Chiang A, Wan M, Sklar J, Neumeister V, Politi K, Goldberg S. HER2 amplification in EGFR mutant NSCLC after acquired resistance (AR) to EGFR-directed therapies. Journal Of Clinical Oncology 2016, 34: 9049-9049. DOI: 10.1200/jco.2016.34.15_suppl.9049.
• Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.Aisner D, Sholl L, Berry L, Haura E, Ramalingam S, Glisson B, Socinski M, Waqar S, Garon E, Cetnar J, Politi K, Schiller J, Rossi M, Chen H, Minna J, Wistuba I, Johnson B, Kris M, Bunn P, Kwiatkowski D. Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience. Journal Of Clinical Oncology 2016, 34: 11510-11510. DOI: 10.1200/jco.2016.34.15_suppl.11510.
• Abstract A083: Modulation of the immune system as a strategy to treat EGFR mutant lung adenocarcinomaAyeni D, Ho P, Perry C, Kaech S, Politi K. Abstract A083: Modulation of the immune system as a strategy to treat EGFR mutant lung adenocarcinoma. Cancer Immunology Research 2016, 4: a083-a083. DOI: 10.1158/2326-6074.cricimteatiaacr15-a083.
• Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0).Kris M, Johnson B, Kwiatkowski D, Wistuba I, Berry L, Haura E, Socinski M, Ramalingam S, Glisson B, Waqar S, Otterson G, Schiller J, Garon E, Cetnar J, Politi K, Brahmer J, Sequist L, Lovly C, Kugler K, Bunn P. Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). Journal Of Clinical Oncology 2015, 33: 8094-8094. DOI: 10.1200/jco.2015.33.15_suppl.8094.
• Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR -mutant lung adenocarcinoma.Goldberg S, Narayan A, Carriero N, Nemati R, Bommakanti A, Wurtz A, Boffa D, Decker R, Herbst R, Juergensmeier J, Politi K, Gettinger S, Patel A. Detection of sensitizing and resistance EGFR mutations from circulating tumor DNA (ctDNA) in blood using multiplexed next-generation sequencing in patients with advanced EGFR -mutant lung adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 8093-8093. DOI: 10.1200/jco.2014.32.15_suppl.8093.
• Thoracic Neoplasia: CarcinomaPoliti K, Dela Cruz C, Homer R. Thoracic Neoplasia: Carcinoma. 2014, 2677-2689. DOI: 10.1016/b978-0-12-386456-7.05310-7.
• Abstract C113: ERBB3 independent activation of the PI3K pathway in EGFR mutant lung adenocarcinomas.Song X, Fan P, Guha U, Threadgill D, Varmus H, Politi K. Abstract C113: ERBB3 independent activation of the PI3K pathway in EGFR mutant lung adenocarcinomas. Molecular Cancer Therapeutics 2013, 12: c113-c113. DOI: 10.1158/1535-7163.targ-13-c113.
• Abstract C90: Dependence of afatinib and cetuximab resistant lung adenocarcinomas on mTOR signaling.Pirazzoli V, Nebhan C, Song X, Walter Z, Cai G, Wurtz A, Zhao Z, Elisa de Stanchina E, Horn L, Carbone D, Stevens P, Miller V, Gettinger S, Pao W, Politi K. Abstract C90: Dependence of afatinib and cetuximab resistant lung adenocarcinomas on mTOR signaling. Molecular Cancer Therapeutics 2013, 12: c90-c90. DOI: 10.1158/1535-7163.targ-13-c90.
• Abstract 933: Modeling acquired resistance to EGFR-directed therapies in mouse models of lung cancer.Pirazzoli V, de Stanchina E, Xia J, Zhao Z, Pao W, Politi K. Abstract 933: Modeling acquired resistance to EGFR-directed therapies in mouse models of lung cancer. Cancer Research 2013, 73: 933-933. DOI: 10.1158/1538-7445.am2013-933.
• Abstract LB-309: Non-covalent wild-type-sparing inhibitors of EGFR T790M .Lee H, Schaefer G, Heffron T, Malek S, Merchant M, Yauch R, Pirazzoli V, Politi K, Settleman J. Abstract LB-309: Non-covalent wild-type-sparing inhibitors of EGFR T790M . Cancer Research 2013, 73: lb-309-lb-309. DOI: 10.1158/1538-7445.am2013-lb-309.
• Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinomade Bruin E, Cowell C, Howell M, Varmus H, Politi K, Downward J. Abstract A18: Reduced NF1 expression in resistance to EGF receptor inhibitory drugs in lung adenocarcinoma. Clinical Cancer Research 2012, 18: a18-a18. DOI: 10.1158/1078-0432.mechres-a18.
• Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancerTakezawa K, Melnick M, Riely G, Kris M, Miller V, Ladanyi M, Politi K, Pao W, Pirazzoli V, Song X, Arcila M, De Stanchina E, Ohashi K, Janjigian Y, Spitzler P, Nebhan C. Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer. Clinical Cancer Research 2012, 18: a23-a23. DOI: 10.1158/1078-0432.mechres-a23.
• Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung AdenocarcinomasPirazzoli V, Takezawa K, de Stanchina E, Pao W, Politi K. Abstract A38: Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas. Clinical Cancer Research 2012, 18: a38-a38. DOI: 10.1158/1078-0432.mechres-a38.
• Abstract 1897: RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancerOhashi K, Chmielecki J, Lin Y, Pan H, Vnencak-Jones C, Arcila M, Wang L, Fernandez L, Keisuke A, Shien K, Yamamoto H, Toyooka S, Kiura K, Thomas R, Yang J, Miller V, Ladanyi M, Politi K, Pao W. Abstract 1897: RAS signaling pathway gene mutations and acquired resistance to EGFR tyrosine-kinase inhibitors in EGFR mutant lung cancer. Cancer Research 2012, 72: 1897-1897. DOI: 10.1158/1538-7445.am2012-1897.
• Abstract B35: Activation of Putative Compensatory Pathways upon Deletion of Erbb3 in Mutant EGFR -driven Lung CancerSong X, Fan P, Guha U, Threadgill D, Varmus H, Politi K. Abstract B35: Activation of Putative Compensatory Pathways upon Deletion of Erbb3 in Mutant EGFR -driven Lung Cancer. Clinical Cancer Research 2012, 18: b35-b35. DOI: 10.1158/1078-0432.12aacriaslc-b35.
• Abstract IA4: Defining the mechanisms of tumorigenesis by mutant EGFR using mouse modelsPoliti K. Abstract IA4: Defining the mechanisms of tumorigenesis by mutant EGFR using mouse models. Clinical Cancer Research 2012, 18: ia4-ia4. DOI: 10.1158/1078-0432.12aacriaslc-ia4.
• Abstract 3166: Lung cancer bio-signatures in plasma based on the analysis of mouse modelsTaguchi A, Politi K, Pitteri S, Lockwood W, Faça V, Sage J, Kemp C, Varmus H, Hanash S. Abstract 3166: Lung cancer bio-signatures in plasma based on the analysis of mouse models. Cancer Research 2011, 71: 3166-3166. DOI: 10.1158/1538-7445.am2011-3166.
• Abstract LB-398: Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancerde Bruin E, Cowell C, Howell M, Varmus H, Politi K, Downward J. Abstract LB-398: Identification of novel mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Research 2011, 71: lb-398-lb-398. DOI: 10.1158/1538-7445.am2011-lb-398.
• Abstract LB-151: Targeted gene resequencing in a K-ras-dependent mouse model of metastatic lung adenocarcinomaMcFadden D, Xuan Z, Rosebrock A, Politi K, Santiago P, Hodges E, Winslow M, Hiramatsu N, Pirun M, Crowley D, Bronson R, Socci N, Varmus H, Hannon G, Jacks T. Abstract LB-151: Targeted gene resequencing in a K-ras-dependent mouse model of metastatic lung adenocarcinoma. Cancer Research 2010, 70: lb-151-lb-151. DOI: 10.1158/1538-7445.am10-lb-151.
• BAC Consensus Conference, November 4???6, 2004: Epidemiology, Pathogenesis, and Preclinical ModelsChristiani D, Pao W, DeMartini J, Linnoila R, Malkinson A, Onn A, Politi K, Sharp M, Kim K. BAC Consensus Conference, November 4???6, 2004: Epidemiology, Pathogenesis, and Preclinical Models. Journal Of Thoracic Oncology 2006, 1: s2-s7. DOI: 10.1097/01243894-200611001-00002.
• Oncogenes Come of AgeVARMUS H, PAO W, POLITI K, PODSYPANINA K, DU Y. Oncogenes Come of Age. Cold Spring Harbor Symposia On Quantitative Biology 2005, 70: 1-9. PMID: 16869733, PMCID: PMC1791364, DOI: 10.1101/sqb.2005.70.039.